Epilepsy

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.

An indirect comparison found zorevunersen-treated patients with Dravet syndrome showed greater gains in adaptive functioning and behavior than natural history patients.

Here's some of what is coming soon to NeurologyLive® this week.

FDA approved Zanvastro (zilganersen), the first therapy to directly target the GFAP protein buildup that drives Alexander disease, based on a phase 3 trial showing improved walking speed and motor function versus untreated controls.

The phase 3 Aspire study of apazunersen did not meet its primary cognition end point or key secondary end point in Angelman syndrome.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is pediatric epilepsy care!

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 28, 2026.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 21, 2026.

Oak Hill Bio announced dosing of the first participant in BEACON, a pivotal phase 3 trial evaluating rugonersen, an antisense oligonucleotide originally developed by Roche, for Angelman syndrome.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 14, 2026.

Uma Menon, MD, Adult Neurology Residency Program Director at Allina Health Brain and Spine Institute, shares lessons on navigating fellowship, finding the right career path, building expertise, and maintaining balance throughout a career in neurology.

In a recently published phase 3 post hoc analysis, treatment with fenfluramine was associated with early, sustained reductions in fall-related seizures among patients with Lennox-Gastaut syndrome.

Cynthia Keator, MD, director of neurology at Cook Children's Hospital, shares her perspective on building longitudinal Lennox-Gastaut syndrome care plans, navigating the pediatric-to-adult transition, and what the field needs to do better for patients and families.

Epilepsy expert Susan Duberstein, MD, explores how multidisciplinary neurocutaneous clinics improve diagnosis, surveillance, care coordination, and long-term outcomes for patients with complex neurocutaneous syndromes.

Ahead of World Brain Day, NeurologyLive explores 5 emerging strategies for preventing neurologic disease, from modifiable dementia risk factors to GLP-1 drugs, sleep science, the gut brain axis, and wearable technology.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 10, 2026.

Led by Na Tosha Gatson, MD, PhD, FAAN, director of the Center for Neuro-Oncology at the Indiana University Health Neurosciences and Cancer Institutes, this new column translates complex neuro-oncology topics into accessible, evidence-based insights.

Cleveland Clinic pilots HAP-E, guiding older adults to manage epilepsy and cognitive decline with lifestyle tools, medication support, and virtual access.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 3, 2026.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 26, 2026.

A pair of neurologists discussed a new analysis suggesting that gender-affirming hormone therapy was not associated with an increased risk of seizure-related hospitalization among transgender women.

Three of 6 patients in the first low-dose cohort achieved seizure reductions of 79% to 100% at months 4 through 6, with no serious adverse events reported to date.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 19, 2026.

Irfan Qureshi, MD, chief medical officer at Biohaven, discusses newly reported data on opakalim, highlighting durable seizure control, favorable CNS tolerability, and the investigational agent’s potential role across multiple epilepsy syndromes.